4//SEC Filing
ENANTA PHARMACEUTICALS INC 4
Accession 0001012975-14-000121
$ENTACIK 0001177648operating
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 5:25 PM ET
Size
29.4 KB
Accession
0001012975-14-000121
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2014-02-25$38.92/sh−27,297$1,062,369→ 361,320 total - Sale
Common Stock
2014-02-25$38.92/sh−36,478$1,419,684→ 482,872 total - Sale
Common Stock
2014-02-25$38.92/sh−112,826$4,391,064→ 1,493,446 total - Sale
Common Stock
2014-02-26$39.93/sh−8,283$330,747→ 353,037 total - Sale
Common Stock
2014-02-26$39.93/sh−11,069$441,994→ 471,803 total - Sale
Common Stock
2014-02-26$39.93/sh−34,237$1,367,111→ 1,459,209 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.44, inclusive. Each Reporting Person undertakes to provide to Enanta Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Alexandra Goll ("Goll") and Helmut Schuhsler ("Schuhsler"), each members of the investment committee of TVM Capital, share voting and investment authority over the shares held by Medical Ventures with the other members of the investment committee. Each of TVM Capital, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
- [F3]The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Goll and Schuhsler, each members of the investment committee of TVM IV Management, share voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Each of TVM IV Management, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
- [F4]The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), Goll and Schuhsler, each members of the investment committee of TVM V Management, share voting and investment authority over the shares held by TVM V. Each of TVM V Management, Birner, Fischer, Goll and Schuhsler disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.25, inclusive. Each Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeoperating
Related Parties
1- filerCIK 0001177648
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 5:25 PM ET
- Size
- 29.4 KB